Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM] [version 1; peer review: 2 approved]

Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM] [version 1; peer review: 2 approved]

Background: Tuberculous meningitis (TBM) is the most lethal form of tuberculosis with a mortality of ~50% in those co-infected with HIV-1. Current antibiotic regimens are based on those known to be effective in pulmonary TB and do not account for the differing ability of the drugs to penetrate the c...

Full description

Bibliographic Details
Main Authors: Angharad G. Davis, Sean Wasserman, Mpumi Maxebengula, Cari Stek, Marise Bremer, Remy Daroowala, Saalikha Aziz, Rene Goliath, Stephani Stegmann, Sonya Koekemoer, Amanda Jackson, Louise Lai Sai, Yakub Kadernani, Thandi Sihoyiya, C.Jason Liang, Lori Dodd, Paolo Denti, Thomas Crede, Jonathan Naude, Patryk Szymanski, Yakoob Vallie, Ismail Banderker, Shiraz Moosa, Peter Raubenheimer, Rachel P.J. Lai, John Joska, Sam Nightingale, Anna Dreyer, Gerda Wahl, Curtis Offiah, Isak Vorster, Sally Candy, Frances Robertson, Ernesta Meintjes, Gary Maartens, John Black, Graeme Meintjes, Robert J. Wilkinson
Format: Article
Language:English
Published: Wellcome 2021-06-01
Series:Wellcome Open Research
Online Access:https://wellcomeopenresearch.org/articles/6-136/v1

Internet

https://wellcomeopenresearch.org/articles/6-136/v1

Similar Items